PresentationNow I will hand the conference over to your host, Marc Jacquot, Managing Partner and Group CFO, to begin today's conference. Please go ahead.Marc JacquotManaging Partner & CFO Good evening, ladies and gentlemen. Thanks for joining us today for Rubis' Q3 and 9 months 2025 trading update. I am Marc Jacquot, Managing Partner and Chief Financial Officer of Rubis, and I'm joined today by Clemence Mignot-Dupeyrot, Head of Investor Relations. Together, we'll walk you through Rubis' financial performanc ...

Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -46.15%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.18, delivering no surprise.Over the last four quarters, the company has surpassed consensus ...

Exagen (NasdaqGM:XGN) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker5Good morning, ladies and gentlemen, and welcome to Exagen Q3 2025 earnings conference call. All participants are in listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please key in star and then zero on your telephone keypad. Please note this event is being recorded. I will now hand you over to Ryan Douglas. Please go ahead.Sp ...

Exagen (NasdaqGM:XGN) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to Exagen Inc. Q3 twenty twenty five Earnings Conference Call. All participants are in listen only mode. A question and answer session will follow the formal presentation. Please note this event is being recorded.I will now hand you over to Ryan Douglas. Please go ahead, sir.Speaker1Good morning and thank you for joining us. Earlier this morning, Exagen Inc. Released financial re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39049 EXAGEN INC. (Exact name of registrant as specified in its charter) Delaware 20-0434866 (State or Other Jurisdiction of Incorporation or Organization) 1261 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

November 4, 2025 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates. | | | | Three Months Ended September 30, | | | | Nine Months Ended September 30, | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 2025 | | 2024 | | 2025 | | 2024 | | (Unaudited, in thousands, except ASP data) | | | | | | | | | | Revenue | $ | 17,244 | $ | 12,507 | $ | 49,94 ...

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates. Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024(Unaudited, in thousands, except ASP data) Revenue $17,244 <td style="max-width:1%; width:1%; min-width:1%;;padding-right: 0 ; text-align: right ; vertical-align: ...

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds the potential to ...

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 201-389-0918Intern ...